NZ309713A - Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine - Google Patents

Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine

Info

Publication number
NZ309713A
NZ309713A NZ309713A NZ30971396A NZ309713A NZ 309713 A NZ309713 A NZ 309713A NZ 309713 A NZ309713 A NZ 309713A NZ 30971396 A NZ30971396 A NZ 30971396A NZ 309713 A NZ309713 A NZ 309713A
Authority
NZ
New Zealand
Prior art keywords
compositions
methods
antigen
pneumoniae serotype
oligosaccharide
Prior art date
Application number
NZ309713A
Inventor
Andrew J Malcolm
Original Assignee
Alberta Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/477,497 external-priority patent/US5866132A/en
Priority claimed from US08/482,626 external-priority patent/US5695768A/en
Priority claimed from CA002153730A external-priority patent/CA2153730A1/en
Priority claimed from CA002153733A external-priority patent/CA2153733A1/en
Application filed by Alberta Res Council filed Critical Alberta Res Council
Priority to NZ337730A priority Critical patent/NZ337730A/en
Publication of NZ309713A publication Critical patent/NZ309713A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The application provides immunogenic oligosaccharide compositions and methods of making and using them. In particular, the compositions comprise oligosaccharides covalently coupled to carrier protein, wherein the resultant conjugate has been shown to contain specific immunogenic epitopes and elicits a protectively immunogenic response. This application also provides compositions comprising an oligosaccharide of S. pneumoniae serotype 8 useful for stimulating an immune response to an antigen, methods of providing protective immunization against a bacterial pathogen using these compositions, methods of augmenting an immunogenic response to an antigen by administering these S. pneumoniae serotype 8 oligosaccharide compositions along with the antigen, and methods of making the immunostimulatory compositions described above.
NZ309713A 1995-06-07 1996-06-06 Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine NZ309713A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ337730A NZ337730A (en) 1995-06-07 1996-06-06 use of an oligosaccharide hapten- carrier conjugate for immunizing against a bacterial or viral pathogen by administering

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/477,497 US5866132A (en) 1995-06-07 1995-06-07 Immunogenic oligosaccharide compositions
US08/482,626 US5695768A (en) 1995-06-07 1995-06-07 Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
CA002153730A CA2153730A1 (en) 1995-07-12 1995-07-12 Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides
CA002153733A CA2153733A1 (en) 1995-07-12 1995-07-12 Immunogenic oligosaccharide compositions
PCT/CA1996/000387 WO1996040225A1 (en) 1995-06-07 1996-06-06 Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them

Publications (1)

Publication Number Publication Date
NZ309713A true NZ309713A (en) 1999-11-29

Family

ID=27427244

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ309713A NZ309713A (en) 1995-06-07 1996-06-06 Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine

Country Status (10)

Country Link
EP (1) EP0831894A1 (en)
JP (1) JPH11506110A (en)
KR (1) KR19990007777A (en)
AU (1) AU725279B2 (en)
CZ (1) CZ327897A3 (en)
IL (1) IL121585A0 (en)
MX (1) MX9707944A (en)
NO (1) NO974727L (en)
NZ (1) NZ309713A (en)
WO (1) WO1996040225A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT939647E (en) 1996-08-27 2002-04-29 Chiron Corp GLYCONPONES OF NEISSERIA MENINGITIDIS SEROGRUPO B AND METHODS OF USE OF THE SAME
CA2297072A1 (en) * 1997-07-17 1999-01-28 North American Vaccine, Inc. Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
JP2002513028A (en) 1998-04-28 2002-05-08 ガレニカ ファーマシューティカルズ， インコーポレイテッド Polysaccharide antigen conjugate
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
WO2001098334A2 (en) * 2000-06-20 2001-12-27 Shire Biochem Inc. Streptococcus antigens
JP2012530785A (en) * 2009-06-22 2012-12-06 ワイス・エルエルシー Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
PL3096785T3 (en) * 2014-01-21 2021-03-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3000820A1 (en) * 2014-09-26 2016-03-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic vaccines against Streptococcus pneumoniae serotype 8
US10220083B2 (en) 2014-09-26 2019-03-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccines against Streptococcus pneumoniae serotype 8
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2017306708B2 (en) 2016-08-05 2021-08-26 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CA3074714A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
MX2020007939A (en) 2018-02-05 2020-09-03 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition.
AU2019215216A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
BR112020021296A2 (en) 2018-04-18 2021-01-26 Sk Bioscience Co., Ltd. capsular polysaccharide of streptococcus pneumoniae and its immunogenic conjugate
JP2022512345A (en) * 2018-12-12 2022-02-03 ファイザー・インク Immunogenic Multiple Heteroantigen Polysaccharide-Protein Conjugates and Their Use
CN113607939A (en) * 2021-08-05 2021-11-05 艾美探索者生命科学研发有限公司 Method for measuring adsorption rate of various combined stock solutions of pneumococcal polysaccharide combined vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187753B (en) * 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
EP0302887B1 (en) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ATE137981T1 (en) * 1990-12-18 1996-06-15 Univ Washington DIALYSAT PRODUCTION SYSTEM WITH PILLS
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine

Also Published As

Publication number Publication date
WO1996040225A1 (en) 1996-12-19
MX9707944A (en) 1998-06-30
NO974727D0 (en) 1997-10-13
CZ327897A3 (en) 1998-02-18
JPH11506110A (en) 1999-06-02
AU725279B2 (en) 2000-10-12
NO974727L (en) 1997-12-08
EP0831894A1 (en) 1998-04-01
IL121585A0 (en) 1998-02-08
AU5994496A (en) 1996-12-30
KR19990007777A (en) 1999-01-25

Similar Documents

Publication Publication Date Title
NZ309713A (en) Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine
IL115047A0 (en) Pneumococcal polysaccharide - recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections.
AU8483391A (en) Improved oligosaccharide conjugate vaccines
GB9713156D0 (en) Vaccines
AU3065489A (en) T-cell epitope as carriers molecule for conjugate vaccines
WO2000056360A3 (en) Vaccine against antigens from bacteriae
AU4841693A (en) Vaccines against group c neisseria meningitidis
ES8707861A1 (en) Immunogenic conjugates of E. coli LT-B enterotoxin subunit and capsular polymers.
CA2033640A1 (en) Vaccines against cancer and infectious diseases
AU2145188A (en) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
CA2285018A1 (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
CA2139217A1 (en) Vaccine composition for eliciting an immune response against n-glycolylated gangliosides and its use for cancer treatment
AU1991097A (en) Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
UA27754C2 (en) Combination pediatric vaccine, method of simultaneous combined vaccination
AU3991899A (en) Verotoxin b subunit for immunization
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
Michon et al. Combination conjugate vaccines against multiple serotypes of group B streptococci
Messner et al. Vaccine development based on S-layer technology
AU2579600A (en) Product and method for obtaining specific immunisation with one or more antigens
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen